跳至主要内容
临床试验/NCT01982916
NCT01982916已完成3 期

A 4 Week Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of AGR Tablet in the Treatment of Perennial Allergic Rhinitis in Korean : a Phase III Clinical Trial Bridging Study

Ahn-Gook Pharmaceuticals Co.,Ltd9 个研究点 分布在 1 个国家目标入组 324 人开始时间: 2013年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
324
试验地点
9
主要终点
Change of 4NTSS(4 Nasal Total Symptoms score) from baseline

研究概览

简要总结

The purpose of this study is to evaluate treatment of perennial allergic rhinitis in Korean patients with AGR tablet.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

AGR & Placebo

Experimental

AGR tablet by qd and Placebo by bid for 4 weeks

干预措施: AGR tablet (Drug)

AGR & Placebo

Experimental

AGR tablet by qd and Placebo by bid for 4 weeks

干预措施: Placebo (for AGR tablet and/or Active Comparator) (Drug)

Placebo

Placebo Comparator

Placebo by bid for 4 weeks

干预措施: Placebo (for AGR tablet and/or Active Comparator) (Drug)

Active comparator

Active Comparator

Active Comparator and Placebo by bid for 4 weeks

干预措施: Placebo (for AGR tablet and/or Active Comparator) (Drug)

Active comparator

Active Comparator

Active Comparator and Placebo by bid for 4 weeks

干预措施: Active Comparator (Drug)

结局指标

主要结局

Change of 4NTSS(4 Nasal Total Symptoms score) from baseline

时间窗: 4 weeks

次要结局

未报告次要终点

研究者

发起方
Ahn-Gook Pharmaceuticals Co.,Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验